CytomX Therapeutics, Inc. (CTMX) has launched a public offering of $250 million in shares and pre-funded warrants, aiming to fund the development of its oncology pipeline, particularly Varseta-M, a treatment for late-line metastatic colorectal cancer. Following the announcement, CTMX shares dipped 2.22% to $6.60, despite a recent rally that saw the stock rise 44.23% to close at $6.75 on Monday.
The company reported a significant shift in its financials for 2025, with a net loss of $17.3 million compared to a net income of $31.8 million in 2024, alongside a revenue decline from $138.1 million to $76.2 million. With $137.1 million in cash and a projected runway into mid-2027, the offering could bolster its financial position as it navigates a challenging market landscape.
For professionals tracking biotech funding and stock performance, this offering may signal both opportunity and risk. I recommend checking out the full article for a deeper dive into CytomX’s strategic plans and financial outlook.
Source: nasdaq.com